- NervGen Pharma (NGEN) appoints Michael Kelly as President and Chief Executive Officer
- Kelly has also been appointed as a member of NervGen’s Board of Directors
- While growing the company, he sold the company assets for $1.2 billion to Concordia Healthcare in 2015
- Kelly was granted 590,000 retention securities, each exercisable into one common share at $1.78 each
- NervGen Pharma (NGEN) is up 1.12 per cent, trading at C$1.80 at 11:21 am EST
NervGen Pharma (NGEN) appoints Michael Kelly to the position of President and CEO.
Kelly has also been appointed as a member of NervGen’s Board of Directors.
NervGen is thrilled to have Michael Kelly join the team and to see what role he will play in the coming future.
“Mike is a highly experienced pharmaceutical executive with a strong track record of leadership and success,” stated Bill Radvak, Executive Chairman.”
“Mike played a key leadership role as President of US operations at Adapt Pharma and its highly successful launch of its Nasal Spray in the US and Canada and eventual sale to Emergent BioSolutions for US$735 million,” continued Radvak.
Kelly currently serves on the Board of Directors of ARS Pharmaceuticals.
He joined back in May 0f 2019 and Prior to Adapt, he was the CEO and Board member for Covis Pharma.
While growing the company, he sold the company assets for $1.2 billion to Concordia Healthcare in 2015.
Radvak added, “We are stepping down from these interim roles with every confidence that Mike Kelly’s expertise and experience make him the ideal candidate to lead NervGen forward.”
Since joining the new role, Kelly was granted 590,000 retention securities, each exercisable into one common share at $1.78 each for 10 years.
NervGen is a clinical stage biotech company dedicated to developing innovative treatments for the nervous system to repair itself following damage.
NervGen Pharma (NGEN) is up 1.12 per cent, trading at C$1.80 at 11:21 am EST.
